BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 11704876)

  • 21. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma.
    Roncalli M; Bianchi P; Bruni B; Laghi L; Destro A; Di Gioia S; Gennari L; Tommasini M; Malesci A; Coggi G
    Hepatology; 2002 Aug; 36(2):427-32. PubMed ID: 12143052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas.
    Nakamura M; Sakaki T; Hashimoto H; Nakase H; Ishida E; Shimada K; Konishi N
    Cancer Res; 2001 Sep; 61(17):6335-9. PubMed ID: 11522621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53-Dependent and -independent functions of the Arf tumor suppressor.
    Sherr CJ; Bertwistle D; DEN Besten W; Kuo ML; Sugimoto M; Tago K; Williams RT; Zindy F; Roussel MF
    Cold Spring Harb Symp Quant Biol; 2005; 70():129-37. PubMed ID: 16869746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of methylated p15 and p16 genes on clinicopathological features in colorectal cancer.
    Ishiguro A; Takahata T; Saito M; Yoshiya G; Tamura Y; Sasaki M; Munakata A
    J Gastroenterol Hepatol; 2006 Aug; 21(8):1334-9. PubMed ID: 16872319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck.
    Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
    Virchows Arch; 2002 Aug; 441(2):133-42. PubMed ID: 12189502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular analysis of the INK4 family of genes in prostate carcinomas.
    Park DJ; Wilczynski SP; Pham EY; Miller CW; Koeffler HP
    J Urol; 1997 May; 157(5):1995-9. PubMed ID: 9112579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma.
    Peng CY; Chen TC; Hung SP; Chen MF; Yeh CT; Tsai SL; Chu CM; Liaw YF
    Anticancer Res; 2002; 22(2B):1265-71. PubMed ID: 12168936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Upregulation of chicken p15INK4b at senescence and in the developing brain.
    Kim SH; Rowe J; Fujii H; Jones R; Schmierer B; Kong BW; Kuchler K; Foster D; Ish-Horowicz D; Peters G
    J Cell Sci; 2006 Jun; 119(Pt 12):2435-43. PubMed ID: 16720639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis.
    Sharpless NE; Ramsey MR; Balasubramanian P; Castrillon DH; DePinho RA
    Oncogene; 2004 Jan; 23(2):379-85. PubMed ID: 14724566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma.
    Tannapfel A; Sommerer F; Benicke M; Weinans L; Katalinic A; Geissler F; Uhlmann D; Hauss J; Wittekind C
    J Pathol; 2002 Aug; 197(5):624-31. PubMed ID: 12210082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of Chr9p21 genes CDKN2B (p15(INK4b)), CDKN2A (p16(INK4a), p14(ARF)) and MTAP in human atherosclerotic plaque.
    Holdt LM; Sass K; Gäbel G; Bergert H; Thiery J; Teupser D
    Atherosclerosis; 2011 Feb; 214(2):264-70. PubMed ID: 20637465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel frameshift mutation in the p16/INK4A tumor suppressor gene in canine breast cancer alters expression from the p16/INK4A/p14ARF locus.
    Lutful Kabir FM; Agarwal P; Deinnocentes P; Zaman J; Bird AC; Bird RC
    J Cell Biochem; 2013 Jan; 114(1):56-66. PubMed ID: 22833492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SH3GL2 and CDKN2A/2B loci are independently altered in early dysplastic lesions of head and neck: correlation with HPV infection and tobacco habit.
    Ghosh A; Ghosh S; Maiti GP; Sabbir MG; Alam N; Sikdar N; Roy B; Roychoudhury S; Panda CK
    J Pathol; 2009 Feb; 217(3):408-19. PubMed ID: 19023882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cloning and characterization of murine p16INK4a and p15INK4b genes.
    Quelle DE; Ashmun RA; Hannon GJ; Rehberger PA; Trono D; Richter KH; Walker C; Beach D; Sherr CJ; Serrano M
    Oncogene; 1995 Aug; 11(4):635-45. PubMed ID: 7651726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The INK4a/ARF locus and melanoma.
    Sharpless E; Chin L
    Oncogene; 2003 May; 22(20):3092-8. PubMed ID: 12789286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detailed gene expression analysis but not microsatellite marker analysis of 9p21 reveals differential defects in the INK4a gene locus in the majority of head and neck cancers.
    Grüttgen A; Reichenzeller M; Jünger M; Schlien S; Affolter A; Bosch FX
    J Pathol; 2001 Jul; 194(3):311-7. PubMed ID: 11439363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas.
    Labuhn M; Jones G; Speel EJ; Maier D; Zweifel C; Gratzl O; Van Meir EG; Hegi ME; Merlo A
    Oncogene; 2001 Mar; 20(9):1103-9. PubMed ID: 11314047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival.
    Grafström E; Egyházi S; Ringborg U; Hansson J; Platz A
    Clin Cancer Res; 2005 Apr; 11(8):2991-7. PubMed ID: 15837753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia.
    Kresty LA; Mallery SR; Knobloch TJ; Song H; Lloyd M; Casto BC; Weghorst CM
    Cancer Res; 2002 Sep; 62(18):5295-300. PubMed ID: 12234999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. INK4a-ARF mutations in skin carcinomas from UV irradiated hairless mice.
    Soufir N; Queille S; Mollier K; Roux E; Sarasin A; de Gruijl FR; Fourtanier AM; Daya-Grosjean L; Basset-Seguin N
    Mol Carcinog; 2004 Apr; 39(4):195-8. PubMed ID: 15057871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.